FDA Safety Database Analysis Reveals Side Effect Profiles of Four CGRP Migraine Drugs
A pharmacovigilance analysis of the FDA FAERS database reveals the real-world safety profiles of four gepant CGRP antagonists used for migraine, identifying both known and potentially new safety signals.
Quick Facts
What This Study Found
FAERS database analysis identified distinct safety profiles for each of the four marketed gepants, with both expected and potentially novel adverse event signals detected.
Key Numbers
How They Did This
Retrospective disproportionality analysis of the FDA FAERS database examining adverse event reports for rimegepant, ubrogepant, atogepant, and zavegepant.
Why This Research Matters
Gepants are relatively new drugs prescribed to millions. Real-world safety data from the FDA's reporting system can detect rare side effects that clinical trials miss, protecting patients.
The Bigger Picture
As CGRP antagonists become mainstream migraine treatment, comprehensive safety surveillance ensures that the benefits of these drugs continue to outweigh risks across diverse real-world patient populations.
What This Study Doesn't Tell Us
FAERS data is voluntary reporting — underreporting is common; cannot determine causation; reporting biases (newer drugs may be over-reported); no denominator (total prescriptions) for incidence calculation.
Questions This Raises
- ?Do the safety signals identified require changes to prescribing guidelines for any specific gepant?
- ?Are there meaningful safety differences between gepants that should guide drug selection?
Trust & Context
- Key Stat:
- 4 gepants compared First comprehensive FAERS analysis comparing all marketed CGRP receptor antagonists
- Evidence Grade:
- Pharmacovigilance database analysis — useful for safety signal detection but cannot establish causation or determine true incidence rates.
- Study Age:
- Published in 2026, providing the most current real-world safety data as gepant prescribing increases rapidly.
- Original Title:
- Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
- Published In:
- Headache (2026)
- Database ID:
- RPEP-14975
Evidence Hierarchy
Frequently Asked Questions
What are gepants?
Gepants are oral or nasal CGRP receptor antagonists that treat migraine by blocking the pain peptide CGRP without constricting blood vessels. Four are currently marketed: rimegepant (Nurtec), ubrogepant (Ubrelvy), atogepant (Qulipta), and zavegepant (Zavzpret).
How reliable is FDA adverse event data?
FAERS captures voluntary reports, so not all side effects are reported. It's excellent for detecting safety signals and comparing drug profiles, but can't determine how common side effects truly are.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14975APA
Chen, Hui; Li, Yan. (2026). Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.. Headache. https://doi.org/10.1111/head.70049
MLA
Chen, Hui, et al. "Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.." Headache, 2026. https://doi.org/10.1111/head.70049
RethinkPeptides
RethinkPeptides Research Database. "Safety analysis of gepants for migraine treatment: A pharmac..." RPEP-14975. Retrieved from https://rethinkpeptides.com/research/chen-2026-safety-analysis-of-gepants
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.